Pathogen Access and Benefit Sharing - Vital Signs

Sign in Subscribe

Pathogen Access and Benefit Sharing

A collection of 3 posts

Inside EU Health: EMA recommends five new medicines: Gilead HIV drug dispute; EU funds for innovative treatments; WHO extends PABS negotiations

Inside EU Health

Inside EU Health: EMA recommends five new medicines: Gilead HIV drug dispute; EU funds for innovative treatments; WHO extends PABS negotiations

EMA recommends five new medicines for approval; MSF denied access to Gilead HIV-prevention drug; Europe invests €244 million to fast-track next-generation treatments for deadly infections; WHO members extend negotiations on pathogen sharing framework